Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Diffuse Large B-Cell Lymphoma

Known as: large cell diffuse lymphoma, DLBCL, Lymphoma, Diffuse Large Cell 
A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes. It is the most frequently seen type… Expand
National Institutes of Health

Related topics

Related topics

38 relations

Narrower (4)

Anaplastic LymphomaAngioendotheliomatosisMalignant lymphoma centroblastic, diffuseT-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Atypical lymphocyteB lymphoblastB-Cell Lymphoma 6 ProteinB-Lymphocytes
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Accuracy of Prediction Instruments for Diagnosing Large Vessel Occlusion in Individuals With Suspected Stroke: A Systematic Review for the 2018 Guidelines for the Early Management of Patients With…
Introduction— Endovascular thrombectomy is a highly efficacious treatment for large vessel occlusion (LVO). LVO prediction… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2018
Review
2018
The clustering of the SDSS-IV extended Baryon Oscillation Spectroscopic Survey DR14 quasar sample: first measurement of baryon acoustic oscillations between redshift 0.8 and 2.2
Author(s): Ata, M; Baumgarten, F; Bautista, J; Beutler, F; Bizyaev, D; Blanton, MR; Blazek, JA; Bolton, AS; Brinkmann, J… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Review
2018
Review
2018
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint has demonstrated unprecedented clinical… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2018
Review
2018
Chimeric antigen receptor T-cell therapies for lymphoma
New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are resistant to standard therapies. Indeed… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2017
Review
2017
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined… Expand
  • figure 1
  • table 1
  • table 1
Is this relevant?
Review
2017
Review
2017
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy is the standard of care in… Expand
Is this relevant?
Review
2017
Review
2017
Chemical approaches to targeted protein degradation through modulation of the ubiquitin–proteasome pathway
Manipulation of the ubiquitin-proteasome system to achieve targeted degradation of proteins within cells using chemical tools and… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
Review
2016
Review
2016
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important subgroups with germinal center B-cell-like… Expand
  • table 1
  • figure 2
  • figure 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE